Email updates

Keep up to date with the latest news and content from BMC Musculoskeletal Disorders and BioMed Central.

Open Access Research article

Improved health outcomes with Etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis

Sang-Cheol Bae1, Suk Chyn Gun2, Chi Chiu Mok3, Rezaul Khandker4, Henk W Nab5, Andrew S Koenig4, Bonnie Vlahos4, Ron Pedersen4 and Amitabh Singh4*

Author Affiliations

1 Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul 133-792, Korea

2 Department of Medicine, Hospital Tuanku Ja’afar Seremban, Seremban, Malaysia

3 Department of Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong

4 Pfizer Inc., Specialty Care Business Unit, 500 Arcola Road, Collegeville, PA, 19426, USA

5 Pfizer Inc., Europe, Rome, Italy

For all author emails, please log on.

BMC Musculoskeletal Disorders 2013, 14:13  doi:10.1186/1471-2474-14-13

Published: 8 January 2013

Abstract

Background

Patient reported outcomes (PROs) are especially useful in assessing treatments for rheumatoid arthritis (RA) since they measure dimensions of health-related quality of life that cannot be captured using strictly objective physiological measures. The aim of this study was to compare the effects of combination etanercept and methotrexate (ETN + MTX) versus combination synthetic disease modifying antirheumatic drugs (DMARDs) and methotrexate (DMARD + MTX) on PRO measures among RA patients from the Asia-Pacific region, a population not widely studied to date. Patients with established moderate to severe rheumatoid arthritis who had an inadequate response to methotrexate were studied.

Methods

Patients were randomized to either ETN + MTX (N = 197) or DMARD + MTX (N = 103) in an open-label, active-comparator, multicenter study, with PRO measures designed as prospective secondary endpoints. The Health Assessment Questionnaire (HAQ), Functional Assessment of Chronic Illness Therapy Fatigue Scale (FACIT-Fatigue), Medical Outcomes Short Form-36 Health Survey (SF-36), Hospital Anxiety and Depression Scale (HADS) and the Work Productivity and Activity Impairment Questionnaire: General Health (WPAI:GH) were used.

Results

Significantly greater improvements were noted for the ETN + MTX group at week16 for HAQ mean scores and for proportion of patients achieving HAQ score ≤ 0.5, compared to patients in the DMARD + MTX group. SF-36 Summary Scores for physical and mental components and for 6 of 8 health domains showed significantly greater improvements at week16 for the ETN + MTX group; only scores for physical functioning and role-emotional domains did not differ significantly between the two treatment arms. Greater improvements at week16 were noted for the ETN + MTX group for FACIT-Fatigue, HADS, and WPAI:GH mean scores.

Conclusion

Combination therapy using ETN + MTX demonstrated superior improvements using a comprehensive set of PRO measures, compared to combination therapy with usual standard of care DMARDs plus MTX in patients with established rheumatoid arthritis from the Asia-Pacific region.

Trial registration

clintrials.gov # NCT00422227

Keywords:
Patient reported outcomes; Etanercept; Rheumatoid arthritis; Asia-Pacific; Health outcomes assessments